![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RW Fuller, SK Hemrick-Luecke and HD Snoddy
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Duloxetine, (+)-N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine, is an inhibitor of the serotonin and norepinephrine neuronal transporters (Wong et al., 1993). In mice, duloxetine antagonized the depletion of brain serotonin by p-chloroamphetamine (ED50 = 2.5 mg/kg, i.p.) and the depletion of heart norepinephrine by 6-hydroxydopamine (ED50 = 1.1 mg/kg, i.p.). Brain concentrations of 5-hydroxyindoleacetic acid were decreased by duloxetine at 2 hr after doses of 1, 3 and 10 mg/kg and at 1 to 8 hr (but not 24 hr) after a 10 mg/kg i.p. dose of duloxetine. Duloxetine antagonized norepinephrine depletion in frontal cortex, but not dopamine depletion in striatum, after treatment of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. In rats, duloxetine decreased brain 5-hydroxyindoleacetic acid dose-dependently for up to 8 hr and decreased serotonin turnover measured by the accumulation of 5- hydroxytryptophan in rat hypothalamus after decarboxylase inhibition. In rats, duloxetine antagonized the depletion of brain serotonin by p- chloramphetamine and the depletion of norepinephrine and epinephrine in hypothalamus after i.c.v. injection of 6-hydroxydopamine. In vitro, duloxetine had little effect on either type A (serotonin as substrate) or type B (phenylethylamine as substrate) monoamine oxidase, IC50 concentrations being above 10(-5) M. These data extend evidence that duloxetine inhibits serotonin and norepinephrine transporters in vivo, actions that may lead to therapeutic efficacy in mental depression.
This article has been cited by other articles:
|
|
 |
|
  P. M. Vis, M. van Baardewijk, and T. R Einarson Duloxetine and Venlafaxine-XR in the Treatment of Major Depressive Disorder: A Meta-Analysis of Randomized Clinical Trials Ann. Pharmacother., November 1, 2005; 39(11): 1798 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Jones, S. C. Peters, and H. E. Shannon Efficacy of Duloxetine, a Potent and Balanced Serotonergic and Noradrenergic Reuptake Inhibitor, in Inflammatory and Acute Pain Models in Rodents J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 726 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vincent, P. R. Bieck, E. M. Garland, C. Loghin, F. P. Bymaster, B. K. Black, C. Gonzales, W. Z. Potter, and D. Robertson Clinical Assessment of Norepinephrine Transporter Blockade Through Biochemical and Pharmacological Profiles Circulation, June 29, 2004; 109(25): 3202 - 3207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Li, L. Ma, R. B. Innis, N. Seneca, M. Ichise, H. Huang, M. Laruelle, and D. L. Murphy Pharmacological and Genetic Characterization of Two Selective Serotonin Transporter Ligands: 2-[2-(Dimethylaminomethylphenylthio)]-5-fluoromethylphenylamine (AFM) and 3-Amino-4-[2-(dimethylaminomethyl-phenylthio)]benzonitrile (DASB) J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 481 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Gehlert, L. Dreshfield, F. Tinsley, M. J. Benvenga, S. Gleason, R. W. Fuller, D. T. Wong, and S. K. Hemrick-Luecke The Selective Norepinephrine Reuptake Inhibitor, LY368975, Reduces Food Consumption in Animal Models of Feeding J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 122 - 127. [Abstract] [Full Text]
|
|
|
|
|
|
L. E. Rueter, C. De Montigny, and P. Blier Electrophysiological Characterization of the Effect of Long-Term Duloxetine Administration on the Rat Serotonergic and Noradrenergic Systems J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 404 - 412. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
